SBIR/STTR Research Award

Natural Adjuvants to Enhance Efficacy of Viral Vaccines for Mariculture

Award identifier 8ea77fc5166bffd5591b0baf5fd5dc9588482b65ae7daadd906403f9d6b61571Awarding agency Department of Commerce · National Oceanic and Atmospheric Administration

Award amount

$298,427

Program and phase

SBIR · Phase II

Award year

2011

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Commerce
Branch
National Oceanic and Atmospheric Administration
Recipient company
ProFishent Inc
Proposal award date
2011-09-16
Contract end date
2013-09-16
UEI
MH3KEAWXKN54
Solicitation number
NOAA 2010-1
Topic code
8.1.2

Research abstract

Marine aquaculture production now exceeds 20 million metric tons annually (FAO 2010) but viral diseases are still a major threat to the expansion of sustainable mariculture systems (National Marine Fisheries Service 2007). Pathogenic viruses continue to devastate many fish and shellfish operations every year (ICES Mariculture Committee 2004, Lightner 2011). To date, vaccines against aquatic animal viruses have generally provided poor protection, are too expensive, and/or must be injected intramuscularly (e.g., DNA vaccines). In response, we will expand and intensify development of innovative biological adjuvant systems initiated in our Phase I trials. We discovered that unique natural marine and terrestrial micro-structures bound to viral antigens can be delivered to gills and mucosal surfaces of salmon to boost specific immune responses against a viral pathogen. We use a nanotechnology-based dynamic light scattering laser instrument to verify attachment of viral antigens or DNA vaccines. Interferon-associated genes and specific antibody titers will be measured by quantitative PCR, ELISA, and virus neutralization tests. Needle-less, immersion immunizations with test formulations will be assessed in fish for safety and efficacy. Multiple, additional in vivo pathogen challenges will be conducted to evaluate new prototype vaccines for relative efficacy and commercialization potential in Phase III field trials.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

10 SBIR/STTR records share this UEI (2000–2012). Reported award amounts total $1,308,325. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Commerce, Department of Agriculture

Agency intelligence

Department of Commerce

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.